Gossamer Bio Stock Surges on FDA Progress and Worldwide Rights Win for Seralutinib
A productive FDA Pre-NDA meeting paves the way for a September 2026 NDA filing for seralutinib in PAH and the return of full rights.
/ 352 items
#XY Event-Driven Stocks↓
Argenx Expands Immunology Pipeline with $2.2B Forte Deal
Argenx acquires Forte Biosciences for $77/share, adding the first-in-class FB102 anti-CD122 antibody to expand its immunology pipeline for autoimmune diseases.
Hims & Hers Shares Plunge After FDA Panel’s First ‘No’ on a Popular Peptide
Hims & Hers shares fell after FDA advisers approved six peptides for compounding but rejected the sleep-related peptide emideltide.
FDA Approves Lytenava: First Official Eye-Only Version of Bevacizumab for Wet AMD
Purpose-built for the eye, it ends years of off-label repackaging.
Lilly’s Next Obesity Blockbuster Retatrutide on Track for 2027 Approval After Five Positive Phase 3 Studies
Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.
FDA Clears MannKind’s Furoscix ReadyFlow — Company Raises $50M to Cover Milestone Payment
Following FDA clearance of Furoscix ReadyFlow for heart failure and CKD edema, MannKind secures $50 million to fund the $45M milestone payment.